Enrico Martin

101 Oncological treatment considerations 15. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys . 1998;42(2):351-360. 16. Zehou O, Fabre E, Zelek L, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis . 2013;8:127. doi:10.1186/1750-1172-8-127 17. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg . 2014;260(3):412-416. doi:10.1097/SLA.0000000000000869 18. Callegaro D, Miceli R, Bonvalot S, et al. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. Eur J Cancer . 2018;105:19-27. doi:10.1016/j.ejca.2018.09.028 19. Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg . 2005;102(2):246-255. doi:10.3171/jns.2005.102.2.0246 20. Montano N, D’Alessandris QG, D’Ercole M, et al. Tumors of the peripheral nervous system: Analysis of prognostic factors in a series with long-term follow-up and review of the literature. J Neurosurg . 2016;125(2):363-371. doi:10.3171/2015.6.JNS15596 21. Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO- EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol Off J Eur Soc Med Oncol . 2018;29(Suppl 4):iv51-iv67. doi:10.1093/ annonc/mdy096 22. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral ner ve sheath tumors in neurofibromatosis. Cancer Res . 2002;62(5):1573-1577. 23. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2016;14(6):758-786. 24. Well L, Salamon J, Kaul MG, et al. Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. Neuro Oncol . 2019;21(4):508-516. doi:10.1093/neuonc/ noy199 25. Brinkman M, Jentjens S, Boone K, et al. Evaluation of the most commonly used (semi-)quantitative parameters of 18F-FDG PET/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1. Nucl Med Commun . 2018;39(11):961-968. doi:10.1097/MNM.0000000000000889 26. Chirindel A, Chaudhry M, Blakeley JO, Wahl R. 18 F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: Comparison of early to delayed imaging with and without liver activity normalization. J Nucl Med . 2015;56(3):379- 385. doi:10.2967/jnumed.114.142372 27. Domanski HA. Fine-needle aspiration cy tolog y of sof t tissue lesions: diagnostic challenges. Diagn Cytopathol . 2007;35(12):768-773. doi:10.1002/ dc.20765 28. Puffer RC, Marek T, Stone JJ, Raghunathan A, Howe BM, Spinner RJ. Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. Acta Neurochir (Wien) . 2018;160(9):1833-1836. doi:10.1007/ s00701-018-3619-4 29. Gerrand CH, Wunder JS, Kandel RA, et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br . 2001;83(8):1149-1155. 5